Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amur Minerals ( (GB:CRTX) ) has shared an announcement.
CRISM Therapeutics has secured Orphan Drug Designation from the U.S. FDA for irinotecan to treat malignant glioma, expanding beyond glioblastoma to cover all high-grade gliomas and marking a key regulatory and commercial milestone for its irinotecan-ChemoSeed programme. Coupled with the UK MHRA’s Innovation Passport under ILAP, the designation is expected to strengthen CRISM’s strategic position, support its Phase 2 registration-grade trial in surgically resectable glioblastoma, and potentially facilitate accelerated, coordinated regulatory review and commercialisation across major global oncology markets.
The most recent analyst rating on (GB:CRTX) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.
Spark’s Take on CRTX Stock
According to Spark, TipRanks’ AI Analyst, CRTX is a Neutral.
The score is held back primarily by weak financial fundamentals (very small revenue with ongoing losses and negative free cash flow), despite improved loss/cash-burn trends and a debt-free balance sheet. Technically, momentum is positive, but the very high RSI suggests near-term overextension. Valuation remains unattractive/unclear due to negative earnings and no indicated dividend support.
To see Spark’s full report on CRTX stock, click here.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage drug delivery company focused on improving cancer treatment for solid tumours through localised and sustained delivery of chemotherapy. Its lead product, ChemoSeed, is an implantable technology designed to deliver high concentrations of chemotherapy directly into tumours or surgical resection margins, including glioblastoma, by bypassing the blood-brain barrier for enhanced therapeutic effect.
Average Trading Volume: 335,841
Technical Sentiment Signal: Hold
Current Market Cap: £6.21M
Learn more about CRTX stock on TipRanks’ Stock Analysis page.